Search

Your search keyword '"Kaji, Kosuke"' showing total 10 results
Start Over Author "Kaji, Kosuke" Journal journal of clinical medicine
10 results on '"Kaji, Kosuke"'

2. ADAMTS13, VWF, and Endotoxin Are Interrelated and Associated with the Severity of Liver Cirrhosis via Hypercoagulability

Author

Takaya, Hiroaki, primary, Namisaki, Tadashi, additional, Asada, Shohei, additional, Iwai, Satoshi, additional, Kubo, Takahiro, additional, Suzuki, Junya, additional, Enomoto, Masahide, additional, Tsuji, Yuki, additional, Fujinaga, Yukihisa, additional, Nishimura, Norihisa, additional, Sawada, Yasuhiko, additional, Kaji, Kosuke, additional, Kawaratani, Hideto, additional, Moriya, Kei, additional, Akahane, Takemi, additional, Matsumoto, Masanori, additional, and Yoshiji, Hitoshi, additional

Published
2022
Full Text
View/download PDF

3. Comparison of Ablation Area and Change in Functional Liver Reserve after Radiofrequency Ablation for Hepatocellular Carcinoma Using the arfa® and VIVA® Systems

Author

Takaya, Hiroaki, primary, Namisaki, Tadashi, additional, Matsumoto, Kazusuke, additional, Suzuki, Junya, additional, Murata, Koji, additional, Tsuji, Yuki, additional, Nakanishi, Keisuke, additional, Kaji, Kosuke, additional, Kitade, Mitsuteru, additional, Noguchi, Ryuichi, additional, and Yoshiji, Hitoshi, additional

Published
2022
Full Text
View/download PDF

4. The Combination of Albumin–Bilirubin Score and Prothrombin Time Is a Useful Tool for Predicting Liver Dysfunction after Transcatheter Arterial Chemoembolization in Child–Pugh Class A Patients with Hepatocellular Carcinoma within Up-to-Seven Criteria

Author

Takaya, Hiroaki, primary, Namisaki, Tadashi, additional, Takeda, Soichi, additional, Kaji, Kosuke, additional, Ogawa, Hiroyuki, additional, Ishida, Koji, additional, Tsuji, Yuki, additional, Takagi, Hirotetsu, additional, Ozutsumi, Takahiro, additional, Fujinaga, Yukihisa, additional, Furukawa, Masanori, additional, Kitagawa, Koh, additional, Nishimura, Norihisa, additional, Sawada, Yasuhiko, additional, Shimozato, Naotaka, additional, Kawaratani, Hideto, additional, Moriya, Kei, additional, Akahane, Takemi, additional, Mitoro, Akira, additional, and Yoshiji, Hitoshi, additional

Published
2021
Full Text
View/download PDF

5. Zinc Administration and Improved Serum Markers of Hepatic Fibrosis in Patients with Autoimmune Hepatitis

Author

Moriya, Kei, primary, Nishimura, Norihisa, additional, Namisaki, Tadashi, additional, Takaya, Hiroaki, additional, Sawada, Yasuhiko, additional, Kawaratani, Hideto, additional, Kaji, Kosuke, additional, Shimozato, Naotaka, additional, Sato, Shinya, additional, Furukawa, Masanori, additional, Douhara, Akitoshi, additional, Akahane, Takemi, additional, Mitoro, Akira, additional, Yamao, Junichi, additional, and Yoshiji, Hitoshi, additional

Published
2021
Full Text
View/download PDF

6. Identification of the Response-Related Biomarker of Bimonthly Hepatic Arterial Infusion Chemotherapy

Author

Moriya, Kei, primary, Namisaki, Tadashi, additional, Takaya, Hiroaki, additional, Kaji, Kosuke, additional, Kawaratani, Hideto, additional, Shimozato, Naotaka, additional, Sawada, Yasuhiko, additional, Douhara, Akitoshi, additional, Sato, Shinya, additional, Furukawa, Masanori, additional, Kitagawa, Koh, additional, Akahane, Takemi, additional, and Yoshiji, Hitoshi, additional

Published
2021
Full Text
View/download PDF

7. Accuracy of Fibrosis-4 Index in Identification of Patients with Cirrhosis Who Could Potentially Avoid Variceal Screening Endoscopy

Author

Ishida, Koji, primary, Namisaki, Tadashi, additional, Murata, Koji, additional, Fujimoto, Yuki, additional, Takeda, Souichi, additional, Enomoto, Masahide, additional, Ogawa, Hiroyuki, additional, Takagi, Hirotetsu, additional, Tsuji, Yuki, additional, Kaya, Daisuke, additional, Fujinaga, Yukihisa, additional, Furukawa, Masanori, additional, Sawada, Yasuhiko, additional, Kitagawa, Koh, additional, Sato, Shinya, additional, Nishimura, Norihisa, additional, Takaya, Hiroaki, additional, Kaji, Kosuke, additional, Shimozato, Naotaka, additional, Kawaratani, Hideto, additional, Moriya, Kei, additional, Akahane, Takemi, additional, Mitoro, Akira, additional, and Yoshiji, Hitoshi, additional

Published
2020
Full Text
View/download PDF

8. Association between Non-Alcoholic Fatty Liver Disease and Chronic Kidney Disease: A Cross-Sectional Study

Author

Akahane, Takemi, primary, Akahane, Manabu, additional, Namisaki, Tadashi, additional, Kaji, Kosuke, additional, Moriya, Kei, additional, Kawaratani, Hideto, additional, Takaya, Hiroaki, additional, Sawada, Yasuhiko, additional, Shimozato, Naotaka, additional, Fujinaga, Yukihisa, additional, Furukawa, Masanori, additional, Kitagawa, Koh, additional, Ozutsumi, Takahiro, additional, Tsuji, Yuki, additional, Kaya, Daisuke, additional, Mitoro, Akira, additional, and Yoshiji, Hitoshi, additional

Published
2020
Full Text
View/download PDF

9. Increased Endotoxin Activity Is Associated with the Risk of Developing Acute-on-Chronic Liver Failure

Author

Takaya, Hiroaki, primary, Namisaki, Tadashi, additional, Sato, Shinya, additional, Kaji, Kosuke, additional, Tsuji, Yuki, additional, Kaya, Daisuke, additional, Fujinaga, Yukihisa, additional, Sawada, Yasuhiko, additional, Shimozato, Naotaka, additional, Kawaratani, Hideto, additional, Moriya, Kei, additional, Akahane, Takemi, additional, Mitoro, Akira, additional, and Yoshiji, Hitoshi, additional

Published
2020
Full Text
View/download PDF

10. Comparison of Ablation Area and Change in Functional Liver Reserve after Radiofrequency Ablation for Hepatocellular Carcinoma Using the arfa ® and VIVA ® Systems.

Author

Takaya, Hiroaki, Namisaki, Tadashi, Matsumoto, Kazusuke, Suzuki, Junya, Murata, Koji, Tsuji, Yuki, Nakanishi, Keisuke, Kaji, Kosuke, Kitade, Mitsuteru, Noguchi, Ryuichi, and Yoshiji, Hitoshi

Subjects
CATHETER ablation, HEPATOCELLULAR carcinoma, LIVER, NON-alcoholic fatty liver disease
Abstract

Radiofrequency ablation (RFA) is recommended in Japan for patients with hepatocellular carcinomas (HCCs) one to three in number and ≤3 cm in size. The arfa® and VIVA® RFA systems are widely used for patients with HCC and this retrospective observational study aims to compare their performances. The study included 365 patients with HCCs one to three in number and ≤3 cm in size who underwent RFA using the arfa® system (arfa® group) or the VIVA® system (VIVA® group). The total bilirubin (T-Bil) level after RFA was higher in the arfa® group than in the VIVA® group. With a 3-cm electrode needle, the longest diameter (Dmax) and the shortest diameter were analyzed and found to be greater in the arfa® group than in the VIVA® group. Furthermore, Dmax with the 2.5-cm electrode needle was greater in the arfa® group than in the VIVA® group. Statistically significant differences in the ablation area and in the T-Bil value after RFA were observed between the groups; however, these differences are not considered clinical problems because the difference in the ablation area was only slight and the Child–Pugh score was the same between the groups. Thus, hepatologists can use either of the RFA systems based on their preference. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results